D.R.I.V.E. Lymphoma and Myeloma Investigators Summit

Dr. Ruemu Birhiray, MD and Dr. Matthew Lunning, DO, FACP invites you to the D.R.I.V.E. Lymphoma and Myeloma Investigators Summit on Wednesday, July 17, 2024.

Disparities in clinical outcomes, research participation and enrollment continue to exist in the treatment of lymphoma amongst ethnically diverse groups. Strategies to address are being developed by many groups including the international/national oncology and hematology medical societies. Additionally, disparate research enrollment has increasing become recognized by government and as a result in 2022, the US congress passed the FDORA act, to help address these disparities, with a requirement for manufactures needing FDA approval of medicines and devices to submit diversity plans for pivotal trials. However, FDORA currently lacks legislated responses to the non-implementation of these diversity plans.

DRIVE is a five-step strategy developed to help address cancer research enrollment disparities and has been published by Indy Hematology Education, Inc. (IHE), a 501(c), non-profit organization, based in Indianapolis. However, IHE recognizes that the widespread adoption of this and other principles requires a collective approach amongst clinical investigators, leading thought leaders and major medical societies. The Pan-Pacific Lymphoma conference, offers a unique opportunity for attending lymphoma and multiple myeloma thought leaders, the leadership of the major hematology and oncology medical societies to discuss and adopt a collective, practical approach to addressing and improving research participation of all people, and an opportunity to generate widely applicable data, and improved data applicability of lymphoma clinical research to patients under our care with data generalizability and transportability and possibly create a template for other disease states.

Date: The Summit will take place on Wednesday, July 17, 2024, at the Hyatt Regency Maui Resort & Spa, 200 Nohea Kai Drive, Lahaina, Hawaii 96761.

AGENDA: CO-CHAIRS: Ruemu E. Birhiray, MD and Matthew Lunning, DO, FACP

(all times are listed in Hawaii-Aleutian Time Zone (HST))

12:30 pm – 1:00 pm - LUNCHEON

1:00-1:05 – INTRODUCTION: Why are we here and what can we all do together to address clinical research disparities in lymphoma research – RUEMU E. BIRHIRAY, MD

1:05-1:20: PRESENTATION OF “CONSENSUS STRATEGY FOR IMPROVING ENROLLMENT IN LYMPHOMA and MYELOMA CLINICAL TRIALS” – Andrew Hantel, MD and Matt Lunning, DO, FACP

1:20-1:40: CONSENSUS STRATEGY: ASCO: What can we do tomorrow: Sybil Green, JD, PharmD, ASCO VICE PRESIDENT FOR DIVERSITY AND EQUITY

1:40-1:50: CONSENSUS STRATEGY: ASH: What can we do tomorrow? ASH PRESIDENT or Nathalie van Havre, MD, MS, FRACP

1:50-2:00: CONSENSUS STRATEGY: FDA: What can we do tomorrow? - NICOLE GROMLEY, MD

2:00-2:10: CONSENSUS STRATEGY: MEDICAL JOURNAL EDITOR-IN-CHIEF: What can we do tomorrow? EDITOR -in Chief Blood Journal - Nancy Berliner, MD, Brigham and Women's Hospital, Boston, MA

OR

2:00-2;10: CONSENSUS STRATEGY: Recommendations for Lymphoma and Myeloma Clinical Research Investigators – Christopher Flowers, MD

2:10-2:25: OUR NEXT STEPS TOMMOROW – ADOPTING AND IMPLEMENTING THE CONSENSUS STRATEGY: Karen Winkfield, MD, PhD

2:25-2:50: DISCUSSIONS AND ADOPTING THE CONSENSUS STRATERGY: ADVISORS

FACILATATORS: Matthew Lunning, DO, FACP, Andrew Hantel, MD. Karen Winkfield, MD, PhD, Christopher Flowers, MD, Ruemu Birhiray, MD

2:50-2:55; CLOSING: Ruemu E. Birhiray, MD and Matthew Lunning, D0, FACP

*Note: The Agenda is subject to change

Questions or to Submit a Case that You Would Like to Discuss: Call 317-841-7171 or email Indyhr@conventionmanagers.com